Table 2 Univariate analysis

From: Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases

  NRM PRM Severe pulmonary complication a ARDS
  % P-value % P-value % P-value % P-value
DRI: low risk+intermediate vs high risk+very−high risk 14.4 (7.4–23.4) vs 9.4 (2.3–22.6) 0.25 5.8 (1.8–13.1) vs 3.1 (0.2–14.2) 0.56 25.9 (16.2–36.7) vs 25.0 (11.5–41.1) 0.55 10.1 (4.4–18.5) vs 3.1 (0.2–14.2) 0.16
Disease: lymphoid vs myeloid 19.8 (8.6–34.4) vs 9.0 (3.6–17.3) 0.04 11.4 (3.5–24.4) vs 1.5 (0.1–7.2) 0.02 39.7 (23.5–55.5) vs 17.9 (9.8–28.0) 0.03 14.2 (5.1–27.8) vs 4.5 (1.2–11.4) 0.04
HCT-CI: 0 vs 1 8.3 (2.1–20.2) vs 15.2 (7.7–24.9) 0.14 0.0 (0.0–0.0) vs 7.6 (2.8–15.6) 0.09 21.7 (10.0–36.3) vs 27.3 (17.1–38.4) 0.39 2.7 (0.2–12.3) vs 10.6 (4.6–19.5) 0.11
Previous pulmonary event: no vs yes 9.4 (3.8–18.1) vs 18.4 (8.0–32.4) 0.5 3.1 (0.6–9.8) vs 7.9 (2.0–19.4) 0.28 21.8 (12.6–32.6) vs 31.6 (17.5–46.7) 0.28 3.1 (0.06–0.09) vs 15.8 (6.3–29.2) <0.01
Age: < vs median (58 years) 15.6 (7.2–26.9) vs 9.8 (3.6–19.9) 0.57 3.9 (0.7–12.0) vs 5.9 (1.5–14.8) 0.65 26.8 (15.5–39.3) vs 24.0 (13.2–36.6) 0.94 7.6 (2.4–16.8) vs 8.0 (2.5–17.7) 0.76
Conditioning regimen: RIC vs MAC 10.7 (5.2–18.4) vs 22.2 (6.6–43.6) 0.11 5.9 (2.2–12.5) vs 0.0 (0.0–0.0) 0.29 24.9 (16.2–34.6) vs 278 (9.6–49.6) 0.97 5.9 (2.2–12.5) vs 16.7 (3.9–37.2) 0.18
Use of ATG: yes vs no 9.5 (4.4–16.9) vs 27.8 (9.7–49.5) 0.12 3.6 (0.9–9.3) vs 11.1 (1.7–30.5) 0.18 23.7 (15.2–33.2) vs 33.3 (13.0–55.3) 0.52 5.9 (2.2–12.4) vs 16.7 (3.9–37.3) 0.18
LFS: 2 vs 3 12.7 (5.1–23.9) vs 12.7 (5.5–23.0) 0.79 4.3 (0.8–13.0) vs 5.5 (1.4–13.8) 0.76 19 (9.3–31.3) vs 30.9 (0.2–0.4) 0.06 6.4 (1.6–15.8) vs 9.1 (3.3–18.5) 0.40
DLCO10s % of predicted normal value: >80% vs 60–80% vs <60% 12.7 (5.1–23.9) vs 12.8 (5.1–24.1) vs 12.5 (0.4–45.3) 0.95 4.3 (0.8–13.0) vs 4.3 (0.8– 13.0) vs 12.5 (0.4–45.3) 0.57 19.0 (9.3–31.3) vs 27.7 (15.7–41.0) vs 50.0 (12.2–79.6) 0.06 6.4 (1.6–15.8) vs 6.4 (1.6–15.9) vs 25.0 (3.0–57.9) 0.20
DLNO % of predicted normal value: >80% vs 60–80% vs <60% 18.2 (8.4–30.9) vs 8.0 (2.5–17.7) vs 11.1 (0.5–40.9) 0.26 9.1 (2.8–19.9) vs 0.0 (0.0–0.0) vs 11.1 (0.5–40.9) 0.07 20.5 (10.0–33.5) vs 24.0 (13.2–36.6) vs 59.3 (13.0–87.4) 0.02 9.1 (2.8–19.9) vs 2.0 (0.2–9.3) vs 35.6 (5.7–68.8) <0.005
  HR P-value HR P-value HR P-value HR P-value
DLCO10s % of predicted normal valueb 1.0 (1.0–1.1) 0.94 1.0 (0.9–1.0) 0.23 1.0 (0.9–1.0) 0.04 1.0 (0.9–1.0) 0.13
DLNO % of predicted normal valueb 1.0 (0.9–1.0) 0.35 1.0 (0.9–1.1) 0.45 2.0 (1.1–3.7) 0.02 1.0 (0.9–1.0) 0.17
DLNO/DLCO ratiob 0.9 (0.5–1.6) 0.7 1.6 (1.0–2.6) 0.04 0.9 (0.5–1.7) 0.78 1.6 (0.6–4.0) 0.34
  1. Abbreviations: ARDS=acute respiratory distress syndrome; ATG=antithymocyte globulin; DLCO=diffusion capacity for carbon monoxide (with correction for hemoglobin concentration); DLNO=diffusion capacity for nitric oxide; DRI=disease risk index;15 LFS=lung function score;13 MAC=myeloablative conditioning; NRM=cumulative incidence of non-relapse mortality; PRM=cumulative incidence of pulmonary related mortality; RIC=reduced intensity regimen.
  2. aDefined by complication requiring hospitalization.
  3. bAnalysis considering continuous variables.